The efficacy of puls methylprednisolone in the treatment of patients with ocular involvement in Behcet's disease
Phase 4
- Conditions
- ocular involvement in behcet's disease.Behcet's disease
- Registration Number
- IRCT201011235235N1
- Lead Sponsor
- Rheumatology Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
Diagnosed Behcet's disease according to international criteria, New or relapse of retinal vasculitis who received any cytotoxic or glucocorticoid since 2 months ago, or new or relapse of severe posterior uveitis who are candidate for cyclophosphamide and azathioprine according to their physician
Exclusion criteria: not Signing the informed consent, Visual acuity lower than 1/10 by Snellen chart, presence of infectious diseases such as TB, presence of diabetes mellitus, hypertension, heart disease, liver disease, renal disease, or edema, presence of other glucocorticoid consumption contraindications
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ocular IBDDAM INDEX. Timepoint: Before and 2 months after treatment. Method of measurement: ophthalmologist record.;Visual acuity. Timepoint: Before intervention and then every 2 months for 6 months. Method of measurement: ophthalmologist record.
- Secondary Outcome Measures
Name Time Method Inflammation in retina. Timepoint: Before and two months after intervention. Method of measurement: ophthalmologist record.